Datroway (datopotamab deruxtecan-dlnk) has been approved in the U.S. for the treatment of adult patients with unresectable or metastatic hormone receptor (HR) positive, HER2 negative (IHC 0, IHC… read more.
Researchers report that adjuvant (post-surgical) trastuzumab emtansine (T-DM1) treatment of women with high-risk HER2-positive breast cancer has reduced their long-term risk of death or invasive disease by 46%… read more.
Novartis announced that the European Commission (EC) has approved Kisqali (ribociclib) in combination with an aromatase inhibitor (AI) for the adjuvant treatment of patients with hormone receptor (HR)-positive,… read more.
Hair loss during chemotherapy can cause enough distress for some women to lose self-confidence, which experts say may discourage them from seeking chemotherapy in the first place. Oral… read more.
Although breast cancer is the most common non-skin cancer diagnosed in women, finding support during treatment and through survivorship can be incredibly challenging. An analysis of posts from… read more.
Three studies led by Dana-Farber Cancer Institute researchers have encouraging implications for patients with breast cancer. Two studies focus on breastfeeding after breast cancer diagnosis and treatment. The studies found… read more.
Giving higher doses per fraction of radiation therapy over a shorter time after breast cancer surgery significantly reduces the risk of side effects and improves quality of life… read more.
Just 28% of U.S. women are aware that a healthful diet can lower the risk of developing breast cancer, according to a just-released Physicians Committee for Responsible Medicine/Morning… read more.
Integration of pharmacies with physician practices, where on-site pharmacies open at physician practice locations, is a growing trend in cancer treatment. However, little is known about how this… read more.
AstraZeneca’s Truqap (capivasertib) in combination with Faslodex (fulvestrant) has been approved in Japan for the treatment of adult patients with unresectable or recurrent PIK3CA, AKT1, or PTEN-altered hormone… read more.
Several studies have described the distinct ways the COVID-19 pandemic adversely impacted cancer care, but less is known about the specific ways the pandemic disrupted breast cancer, the… read more.
Annual breast cancer screening beginning at age 40 and continuing to at least age 79 results in the highest reduction in mortality with minimal risks, according to a… read more.
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
